Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
- 11 December 2024 - 1 mins read
The purpose of the study is to evaluate the efficacy and tolerability of the combination of Lanreotide Autogel 120 mg and Temozolomide in patients with progressive gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) graded as G1 or G2 (G1/G2). All progressive tumours classified according to Response Evaluation Criteria In Solid Tumours (RECIST, 1.1).
11 December 2024
1 mins read
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
11 December 2024
1 mins read
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
11 December 2024
1 mins read
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
11 December 2024
1 mins read
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
11 December 2024
1 mins read
Dysport® Adult Lower Limb Spasticity Follow-on Study
11 December 2024
1 mins read
Dysport® Pediatric Lower Limb Spasticity Study
11 December 2024
1 mins read
Dysport® Adult Lower Limb Spasticity Study
11 December 2024
1 mins read
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
11 December 2024
1 mins read
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
11 December 2024
1 mins read